<DOC>
	<DOCNO>NCT00425347</DOCNO>
	<brief_summary>To identify MTD HuLuc63 administer intravenously ( IV ) 4 doses.2 . To evaluate safety HuLuc63 IV give every week 4 dos .</brief_summary>
	<brief_title>Phase I , Multi-Center , Open-Label , Dose Escalation Study HuLuc63 Subjects With Advanced Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Eligible subject consider inclusion study meet follow criterion : Males female , age 18 year old . Diagnosis advance multiple myeloma , least 2 prior therapy MM . Measurable disease M component serum ( least 0.5 G/dL ) and/or urine ( ≥0.2 g excrete 24hour collection sample ) . Not eligible stem cell bone marrow transplant refuse stem cell bone marrow transplant relapse autologous allogeneic stem cell bone marrow transplant . ECOG performance status 02 ( Appendix E ) . ALT AST ≤3 x ULN . Total bilirubin ≤2 x ULN ( unless relate MM ) . Serum creatinine ≤2.0 mg/dL ( unless relate MM , ≤ 3.0 mg/dL ) . Must adequate bone marrow function define : Absolute neutrophil count &gt; 1,000 cells/mm3 ; platelet ≥75,000 cells/mm3 ; hemoglobin ≥8 g/dL . No platelet transfusion within 72 hour obtain screen platelet count . Serum calcium ( correct albumin ) level within normal range ( treatment hypercalcemia allow subject may enroll hypercalcemia return normal treatment ) . Signed date informed consent . Use appropriate contraception applicable . Negative pregnancy test within 48 hour prior first dose woman childbearing potential . Must 2dimensional echocardiogram MUGA indicate LVEF ≥ 45 % within 30 day prior first dose study drug . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) . Subjects ineligible study meet one follow criterion : Life expectancy le 3 month . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject diseasefree least 5 year . Plasma cell leukemia ( active prior ) . Uncontrolled medical problem diabetes mellitus , coronary artery disease , hypertension , unstable angina , arrhythmia , pulmonary , hepatic , renal disease unless renal insufficiency felt secondary multiple myeloma ( serum creatinine &gt; 2.0 mg/dL ) . Solitary bone solitary extramedullary plasmacytoma evidence plasma cell dyscrasia . Corticosteroid , Velcade® proteosome inhibitor , thalidomide , lenalidomide ( Revlimid® ) , melphalan within 2 week first dose HuLuc63 ; nitrogen mustard agent within 6 week first dose HuLuc63 . Investigational drug within 4 week 5 halflives ( whichever great ) first dose HuLuc63 . Stem cell bone marrow transplant within 12 week prior first dose HuLuc63 . Biological agent include intravenous immune globulin ( IVIG ) monoclonal antibody within 4 week first dose HuLuc63 . Neuropathy &gt; Grade 2 ( accord NCI CTCAE v3.0 criterion scale ) . Symptomatic orthostatic hypotension . Evidence amyloidosis . Known active infection require antibiotic , antiviral , antifungal . Serious psychiatric illness , active alcoholism , drug addiction may hinder confuse followup evaluation . Hypersensitivity recombinant proteins excipients investigational agent . Any condition investigator 's opinion make subject unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Multiple myeloma , MM , plasma cell myeloma , cancer</keyword>
</DOC>